Amid Warfarin Inertia, Bristol/Pfizer Price Eliquis On Par With Pradaxa
This article was originally published in The Pink Sheet Daily
Executive Summary
Eliquis is set to become widely available in the U.S. market at the end of January, with pricing similar to other new oral anticoagulants, despite competitive advantages. Cost and safety concerns help explain why warfarin continues to dominate the market.